[go: up one dir, main page]

AU2001272369A1 - Methods and formultations with probiotic microorganisms and medicaments - Google Patents

Methods and formultations with probiotic microorganisms and medicaments

Info

Publication number
AU2001272369A1
AU2001272369A1 AU2001272369A AU7236901A AU2001272369A1 AU 2001272369 A1 AU2001272369 A1 AU 2001272369A1 AU 2001272369 A AU2001272369 A AU 2001272369A AU 7236901 A AU7236901 A AU 7236901A AU 2001272369 A1 AU2001272369 A1 AU 2001272369A1
Authority
AU
Australia
Prior art keywords
medicament
reducing
organisms
species
microbial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272369A
Other languages
English (en)
Inventor
Svend Laulund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chr Hansen AS
Original Assignee
HANSENS LAB
Chr Hansen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANSENS LAB, Chr Hansen AS filed Critical HANSENS LAB
Publication of AU2001272369A1 publication Critical patent/AU2001272369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001272369A 2000-07-17 2001-07-11 Methods and formultations with probiotic microorganisms and medicaments Abandoned AU2001272369A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21852600P 2000-07-17 2000-07-17
DKPA200001106 2000-07-17
US60218526 2000-07-17
DKPA200001106 2000-07-17
PCT/DK2001/000482 WO2002005829A2 (fr) 2000-07-17 2001-07-11 Procede permettant de reduire les changements dans la flore gastro-intestinale nuisibles du point de vue ecologique intervenus chez des patients suivant un traitement medicamenteux

Publications (1)

Publication Number Publication Date
AU2001272369A1 true AU2001272369A1 (en) 2002-01-30

Family

ID=26068855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272369A Abandoned AU2001272369A1 (en) 2000-07-17 2001-07-11 Methods and formultations with probiotic microorganisms and medicaments

Country Status (5)

Country Link
US (1) US20020022019A1 (fr)
EP (1) EP1303285A2 (fr)
AU (1) AU2001272369A1 (fr)
CA (1) CA2416120A1 (fr)
WO (1) WO2002005829A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7740838B2 (en) * 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
ES2285460T3 (es) * 2003-05-22 2007-11-16 Synbiotics Ab Composicion probiotica que comprende al menos dos cepas bacterianas de acido lactico capaces colonizar tractos gastrointestinales junto con posesion de propiedades de supervivencia intestinal, de union intestinal, de proteccion frente a infecciones y de fermentacion de fibras.
US20060165661A1 (en) * 2003-06-13 2006-07-27 N>V> Nutricia Pediocin-producing pediococci
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
WO2006040816A1 (fr) 2004-10-13 2006-04-20 Kabushiki Kaisha Yakult Honsha Additif pour aliments animaux et aliment pour animaux contenant ledit additif
EP1885383B1 (fr) 2005-05-31 2016-09-21 IAMS Europe B.V. Bifidobacteries de probiotiques felins
EP1880001B1 (fr) 2005-05-31 2011-06-08 The Iams Company Lactobacilli felins à activité probiotique
US8246946B2 (en) 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
US8586029B2 (en) * 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8227235B2 (en) * 2008-12-10 2012-07-24 Alpharma, Llc Compositions and methods for controlling diseases in animals
US20120027737A1 (en) * 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
LT4032586T (lt) 2010-02-01 2025-11-10 Bakterioterapija clostridium difficile kolitui gydyti
EP3424515A3 (fr) 2010-08-04 2019-06-19 Thomas Julius Borody Dispositifs de collecte des selles et leurs möthodes d'utilisation.
MX2013010343A (es) 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
ITMI20110679A1 (it) * 2011-04-20 2012-10-21 Giovanni Mogna Composizione comprendente batteri probiotici in grado di ripristinare l effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell iperacidita gastrica.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
WO2013176774A1 (fr) 2012-05-25 2013-11-28 Arizona Board Of Regents Marqueurs de microbiome et thérapies pour troubles du spectre autistique
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102291174B1 (ko) 2013-06-05 2021-08-18 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt), 조성물 및 제조방법
US9636368B2 (en) * 2014-08-22 2017-05-02 Food Industry Research And Development Institute Strain of Lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout
JP6692897B2 (ja) 2015-05-14 2020-05-13 クレストヴォ・ホールディングス・エルエルシー 便フローラを移植するための組成物、並びにそれを調製及び使用する方法、並びにそれを送達するためのデバイス
HUE058209T2 (hu) 2015-05-22 2022-07-28 Univ Arizona State Módszerek az autizmus spektrum zavar és azzal összefüggõ tünetek kezelésére
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102066242B1 (ko) 2015-06-09 2020-01-14 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(mrt) 조성물 및 제조 방법
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
MA45334A (fr) 2016-03-24 2019-01-30 Probiotical Spa Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
WO2018014012A1 (fr) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Compositions de glycolipide et procédés d'utilisation
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et procédés pour traiter la cholangite sclérosante primitive et des troubles associés
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018187467A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la maladie de parkinson (pd) et des troubles associés
WO2018187464A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la diverticulite et des troubles associés
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
AU2018313766A1 (en) 2017-08-07 2020-02-20 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
MX2022000756A (es) 2019-07-19 2022-03-11 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061894A (en) * 1963-03-01 1967-03-15 Lucien Nouvel Therapeutically active bacterial preparations
JP3083169B2 (ja) * 1991-02-27 2000-09-04 日清製粉株式会社 ビフィズス菌製剤およびその製法
IT1265092B1 (it) * 1993-05-31 1996-10-30 Giuliani Spa Preparato per uso come integratore alimentare, o dietetico,a rilascio mirato nel colon
AUPM596894A0 (en) * 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
IT1270216B (it) * 1994-06-14 1997-04-29 Recordati Chem Pharm Metodo di stabilizzazione di composti biologicamente attivi mediante microgranuli ricoperti sospendibili in fluidi alimentari
AT405235B (de) * 1995-11-02 1999-06-25 Helmut Dr Viernstein Probiotisch wirksame formulierung
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
ATE206873T1 (de) * 1997-01-09 2001-11-15 Nestle Sa Probiotik enthaltendes getreideprodukt
AT407008B (de) * 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen

Also Published As

Publication number Publication date
CA2416120A1 (fr) 2002-01-24
US20020022019A1 (en) 2002-02-21
WO2002005829A3 (fr) 2002-05-02
WO2002005829A2 (fr) 2002-01-24
EP1303285A2 (fr) 2003-04-23

Similar Documents

Publication Publication Date Title
US20020022019A1 (en) Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments
US9649348B2 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
Rolfe The role of probiotic cultures in the control of gastrointestinal health
EP2776048B1 (fr) Compositions pharmaceutiques contenant pediococcus et procédés pour réduire les symptômes de syndromes gastro-entérologiques
US6613549B2 (en) Probiotic therapy for newborns
De Vrese et al. Probiotics and non-intestinal infectious conditions
US20200121740A1 (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US12128077B2 (en) Strains, composition and method of use
EP2349295B1 (fr) Préparation pharmaceutique comprenant une combinaison de souches de streptococcus et de souches de lactobacillus
US20230241135A1 (en) A composition for reducing the risk of urinary tract infection and vaginal infection in women
Ranasinghe et al. Prophylactic use of yoghurt reduces antibiotic induced diarrhoea in children
HK40020295A (en) Pharmaceutical compositions containing pediococcus for reducing the symptoms of gastroenterological syndromes
Kroeker et al. Treatment of Ulcerative Colitis
CODE Oral Probiotics on the Horizon: A Review
Olmstead et al. Probiotics and Antibiotic-Associated Diarrhea

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application